Nochioka K, Sakata Y, Miura M, et al. - Whether impaired glucose tolerance (IGT) holds prognostic value with reference to albuminuria in patients with chronic heart failure (CHF), was determined in this subanalysis of the SUPPORT (supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan) trial, wherein, additive influence of olmesartan in hypertensive patients with symptomatic CHF managed with β-blockers and/or angiotensin-converting enzyme inhibitors was evaluated. A total of 535 CHF patients with mean age 66 years (women 25%) included in the control arm of the SUPPORT trial were analyzed. For a composite outcome of all-cause mortality, myocardial infarction, stroke, and HF hospitalization, researchers assessed the link between glycaemic abnormality (evaluated by 75 g of oral glucose tolerance test) and albuminuria. Findings revealed a link of IGT with poor prognosis when complicated by albuminuria in CHF patients. This implies that with regard to the management of CHF, combined early stages of glucose intolerance and renal dysfunction are important.